Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Precigen (NASDAQ: PGEN) announced its participation in two upcoming virtual fireside chats to discuss their recently FDA-approved therapy for adult recurrent respiratory papillomatosis. The first event, hosted by Jennifer Kim of Cantor, is scheduled for August 27, 2025, while the second chat, moderated by Dr. Swayampakula Ramakanth of H.C. Wainwright, will take place on September 2, 2025.
Both events will feature presentations from Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer. Investors can access the live webcasts through Precigen's investor relations website.
Precigen (NASDAQ: PGEN) ha annunciato la partecipazione a due prossimi incontri virtuali per discutere della terapia recentemente approvata dalla FDA per la papillomatosi respiratoria ricorrente negli adulti. Il primo evento, condotto da Jennifer Kim di Cantor, 猫 in programma per il 27 agosto 2025, mentre il secondo, moderato dal Dr. Swayampakula Ramakanth di H.C. Wainwright, si terr脿 il 2 settembre 2025.
In entrambi gli appuntamenti interverranno Helen Sabzevari, PhD, President and CEO, e Phil Tennant, Chief Commercial Officer. Gli investitori potranno seguire le webcast in diretta dal sito web per gli investitori di Precigen.
Precigen (NASDAQ: PGEN) anunci贸 su participaci贸n en dos pr贸ximos coloquios virtuales para hablar sobre su terapia recientemente aprobada por la FDA para la papilomatosis respiratoria recurrente en adultos. El primer evento, presentado por Jennifer Kim de Cantor, est谩 programado para el 27 de agosto de 2025, y el segundo, moderado por el Dr. Swayampakula Ramakanth de H.C. Wainwright, tendr谩 lugar el 2 de septiembre de 2025.
En ambos eventos participar谩n Helen Sabzevari, PhD, President and CEO, y Phil Tennant, Chief Commercial Officer. Los inversores podr谩n acceder a las retransmisiones en directo a trav茅s del sitio web de relaciones con inversores de Precigen.
Precigen (NASDAQ: PGEN)鞚� 靹膘澑鞚� 鞛皽靹� 順疙潯旮� 鞙犽憪膦呾 旃橂鞝滊 斓滉芳 FDA 鞀轨澑鞚� 氚涭潃 鞁犾暯鞚� 雲检潣頃橁赴 鞙勴暣 鞓堨爼霅� 霊� 瓯挫潣 臧�靸� 韺岇澊鞏挫偓鞚措摐 毂楈棎 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 觳� 氩堨Ц 頄夓偓電� Cantor鞚� Jennifer Kim鞚� 歆勴枆頃橂┌ 2025雲� 8鞗� 27鞚�鞐�, 霊� 氩堨Ц 頄夓偓電� H.C. Wainwright鞚� Dr. Swayampakula Ramakanth臧� 靷殞毳� 毵§晞 2025雲� 9鞗� 2鞚�鞐� 鞐措雼堧嫟.
霊� 頄夓偓鞐愲姅 Helen Sabzevari 氚曥偓, President and CEO鞕赌 Phil Tennant, Chief Commercial Officer臧� 氚滍憸鞛愲 彀胳棳頃╇媹雼�. 韴瀽鞛愲摛鞚� Precigen鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 靸濎瓿� 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨姷雼堧嫟.
Precigen (NASDAQ: PGEN) a annonc茅 sa participation 脿 deux entretiens virtuels 脿 venir pour 茅voquer sa th茅rapie r茅cemment approuv茅e par la FDA contre la papillomatose respiratoire r茅currente chez l'adulte. Le premier 茅v茅nement, anim茅 par Jennifer Kim de Cantor, est pr茅vu le 27 ao没t 2025, et le second, mod茅r茅 par le Dr Swayampakula Ramakanth de H.C. Wainwright, se tiendra le 2 septembre 2025.
Les deux sessions incluront des pr茅sentations de Helen Sabzevari, PhD, President and CEO, et de Phil Tennant, Chief Commercial Officer. Les investisseurs pourront acc茅der aux webcasts en direct via le site relations investisseurs de Precigen.
Precigen (NASDAQ: PGEN) gab bekannt, an zwei bevorstehenden virtuellen Fireside-Chats teilzunehmen, um 眉ber die k眉rzlich von der FDA zugelassene Therapie bei rezidivierender respiratorischer Papillomatose bei Erwachsenen zu sprechen. Die erste Veranstaltung, moderiert von Jennifer Kim von Cantor, ist f眉r den 27. August 2025 geplant, die zweite, geleitet von Dr. Swayampakula Ramakanth von H.C. Wainwright, findet am 2. September 2025 statt.
Bei beiden Terminen werden Helen Sabzevari, PhD, President and CEO, und Phil Tennant, Chief Commercial Officer pr盲sentieren. Investoren k枚nnen die Live-Webcasts 眉ber Precigens Investor-Relations-Website verfolgen.
- None.
- None.
Cantor Virtual Fireside Chat
August 27, 2025, 11 AM 鈥� 12 PM ET
Host: Jennifer Kim, Biotech Analyst, Cantor
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen
H.C. Wainwright Virtual Fireside Chat
September 2, 2025, 11 AM 鈥� 12 PM ET
Moderator: Swayampakula Ramakanth, PhD, Managing Director, Equity Research, H.C. Wainwright
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen
Participants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section at .
Precigen: Advancing Medicine with Precision庐
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit 听辞谤 follow us on 听辞谤 .
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
[email protected]
Media Contact:
Donelle M. Gregory
[email protected]
View original content to download multimedia:
SOURCE Precigen, Inc.
FAQ
When are Precigen's (PGEN) upcoming virtual fireside chats scheduled for?
Who will be presenting at Precigen's (PGEN) virtual fireside chats?
What will be discussed at Precigen's (PGEN) virtual fireside chats?
How can investors access Precigen's (PGEN) virtual fireside chats?
